Comparative Pharmacology
Head-to-head clinical analysis: HYDROCODONE BITARTRATE AND ASPIRIN versus WESTADONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROCODONE BITARTRATE AND ASPIRIN versus WESTADONE.
HYDROCODONE BITARTRATE AND ASPIRIN vs WESTADONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocodone is a mu-opioid receptor agonist; aspirin irreversibly inhibits cyclooxygenase-1 (COX-1) and COX-2, reducing prostaglandin synthesis.
Mu-opioid receptor agonist; also acts as an NMDA receptor antagonist and inhibits serotonin and norepinephrine reuptake.
One to two tablets (hydrocodone bitartrate 5-10 mg / aspirin 500 mg) orally every 4-6 hours as needed for pain; maximum daily dose: 8 tablets (hydrocodone 40 mg, aspirin 4000 mg).
Oral: 2.5-10 mg every 4-6 hours as needed for pain; maximum 40 mg per day.
None Documented
None Documented
Hydrocodone: terminal elimination half-life of approximately 3.8-4.5 hours (range 3.3-4.4 hours in adults) in healthy individuals; prolonged in hepatic impairment and elderly. Aspirin: 15-20 minutes for parent drug; salicylate half-life is dose-dependent (2-3 hours at low doses, up to 15-30 hours at anti-inflammatory doses).
Terminal elimination half-life: 15-60 hours (mean ~24 hours). Clinical context: Prolonged half-life supports once-daily dosing in opioid maintenance; accumulation occurs with repeated dosing due to long half-life.
Hydrocodone: primarily renal (up to 60% as unchanged drug and metabolites, including norhydrocodone, hydromorphone, and conjugates); <10% biliary/fecal. Aspirin: renal excretion of salicylate and its conjugates (salicyluric acid, salicyl phenolic glucuronide, etc.); dose-dependent elimination kinetics.
Primarily renal (40-50% as unchanged methadone and its metabolites, 15-20% as metadone-N-oxide), biliary/fecal (5-10%).
Category D/X
Category C
Opioid Agonist
Opioid Agonist